Vaxart shares slide after first-quarter earnings miss

38
9
Favorite

Vaxart shares slide after first-quarter earnings miss

seekingalpha2021-05-03

(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（9）

xCass
·2021-05-04
Great!
Reply
1
Report
Soksok
·2021-05-04
Good
Reply
1
Report
Fold Replies
- LCT15:
  rly
  2021-05-04
  Reply
  Report
sharonyim
·2021-05-04
pls like me ?
Reply
3
Report
Fold Replies
- LCT15:
  ok
  2021-05-04
  Reply
  Report
S土豪熊貓G
·2021-05-03
Buy buy buy to leverage. Congress on 4-6May. Don’t regret. Buy and hold
Reply
3
Report
Elgk
·2021-05-03
Likeyyy
Reply
2
Report
WalkingIn
·2021-05-03
Ok
Reply
4
Report
WalkingIn
·2021-05-03
Ok
Reply
3
Report
chriscf89
·2021-05-03
Like please
Reply
6
Report
Fold Replies
- Darrenneoyo:
  ya
  2021-05-03
  Reply
  Report
- Insatiable:
  Ok
  2021-05-03
  Reply
  Report
EAtan
·2021-05-03
Good news
Reply
4
Report
Fold Replies
- Darrenneoyo:
  yes
  2021-05-03
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1121188867?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-03 21:51","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1121188867","market":"us","top_or_hot":-1,"title":"Vaxart shares slide after first-quarter earnings miss","media":"seekingalpha","content":"<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXRT","symbol_name":"Vaxart, Inc","start_time":0,"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","article_id":"1121188867","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","pubTimestamp":1620049912,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXRT":"Vaxart, Inc"},"translate_title":"Vaxart第一季度业绩不佳后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":106973037,"gmtCreate":1620086528029,"gmtModify":1704338338307,"author":{"id":"3575793577969306","authorId":"3575793577969306","name":"xCass","avatar":"https://static.tigerbbs.com/4d13a4236fd5fe0391b573daccd86bfc","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106973037","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":106986561,"gmtCreate":1620084375953,"gmtModify":1704338279766,"author":{"id":"3579684763801587","authorId":"3579684763801587","name":"Soksok","avatar":"https://static.tigerbbs.com/03c4a8d2787d3c5042bccff3b0bb60f1","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/106986561","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4213855,"gmtCreate":1620086296112,"gmtModify":1680786849877,"authorId":3581496418554017,"author":{"id":3581496418554017,"authorId":3581496418554017,"name":"LCT15","avatar":"https://static.tigerbbs.com/c80d0fa5d2104afed54088e78f8c338b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":106986561,"type":1,"supId":0,"prevId":0,"content":"<u>rly</u>","text":"<u>rly</u>","html":"<u>rly</u>"}],"langContent":"EN"},{"id":106079316,"gmtCreate":1620081337035,"gmtModify":1704338205444,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"pls like me ?","listText":"pls like me ?","text":"pls like me ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/106079316","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4213858,"gmtCreate":1620086319824,"gmtModify":1663226235669,"authorId":3581496418554017,"author":{"id":3581496418554017,"authorId":3581496418554017,"name":"LCT15","avatar":"https://static.tigerbbs.com/c80d0fa5d2104afed54088e78f8c338b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":106079316,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":108735126,"gmtCreate":1620053544065,"gmtModify":1704337990097,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Buy buy buy to leverage. Congress on 4-6May.&nbsp;Don’t regret. Buy and hold","listText":"Buy buy buy to leverage. Congress on 4-6May.&nbsp;Don’t regret. Buy and hold","text":"Buy buy buy to leverage. Congress on 4-6May. Don’t regret. Buy and hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108735126","repostId":1121188867,"repostType":2,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108701656,"gmtCreate":1620052095675,"gmtModify":1704337956704,"author":{"id":"3582942802538500","authorId":"3582942802538500","name":"Elgk","avatar":"https://static.tigerbbs.com/f4e8020d7d7938b137783287f1ce6264","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Likeyyy","listText":"Likeyyy","text":"Likeyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108701656","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108479315,"gmtCreate":1620051453637,"gmtModify":1704337939022,"author":{"id":"3581413944630908","authorId":"3581413944630908","name":"WalkingIn","avatar":"https://static.tigerbbs.com/74ca2c98f1ef1d4b5f17b3666953d588","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108479315","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108470784,"gmtCreate":1620051437148,"gmtModify":1704337938860,"author":{"id":"3581413944630908","authorId":"3581413944630908","name":"WalkingIn","avatar":"https://static.tigerbbs.com/74ca2c98f1ef1d4b5f17b3666953d588","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108470784","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108450531,"gmtCreate":1620050589023,"gmtModify":1704337910283,"author":{"id":"3571872446256788","authorId":"3571872446256788","name":"chriscf89","avatar":"https://static.tigerbbs.com/c4ed19236bd81f6b2d8ef0433991b5bb","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/108450531","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4210235,"gmtCreate":1620051300950,"gmtModify":1680786796123,"authorId":3572866150582582,"author":{"id":3572866150582582,"authorId":3572866150582582,"name":"Darrenneoyo","avatar":"https://static.tigerbbs.com/19498d498955308da03ff537c16af7b0","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.37%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108450531,"type":1,"supId":4210154,"prevId":0,"content":"<u>ya</u>","text":"<u>ya</u>","html":"<u>ya</u>"},{"id":4210154,"gmtCreate":1620050785513,"gmtModify":1680786790854,"authorId":3572947112309904,"author":{"id":3572947112309904,"authorId":3572947112309904,"name":"Insatiable","avatar":"https://static.tigerbbs.com/72bad41ab9e3c21381076eb68ffe1cdd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108450531,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":108423443,"gmtCreate":1620050127782,"gmtModify":1704337897939,"author":{"id":"3581675380573827","authorId":"3581675380573827","name":"EAtan","avatar":"https://static.tigerbbs.com/615cf622d9cd2d752640bc9d0ec3e1e9","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/108423443","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4210237,"gmtCreate":1620051309829,"gmtModify":1680786790363,"authorId":3572866150582582,"author":{"id":3572866150582582,"authorId":3572866150582582,"name":"Darrenneoyo","avatar":"https://static.tigerbbs.com/19498d498955308da03ff537c16af7b0","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.37%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108423443,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":38,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}